| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 NCT06785636 | Pathos AI, Inc. | Phase 1 / Phase 2 |
| Recruiting | 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prost NCT06706921 | VA Greater Los Angeles Healthcare System | Phase 4 |
| Recruiting | Association Between the SPHERTEST in Vitro Test and Response to Checkpoint Inhibitor Treatments in Patients Wi NCT06738797 | Centre Hospitalier Universitaire de Nīmes | — |
| Recruiting | CD70-targeted immunoPET Imaging of Kidney Cancer NCT06680089 | RenJi Hospital | Phase 2 |
| Recruiting | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma NCT06676527 | Jinling Hospital, China | — |
| Recruiting | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer NCT06353906 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab NCT06237920 | The Netherlands Cancer Institute | Phase 2 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy NCT05887245 | Centre of Postgraduate Medical Education | — |
| Recruiting | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Part NCT05592626 | Marengo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies NCT04923178 | National Cancer Institute (NCI) | — |
| Recruiting | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection NCT05413850 | Blue Earth Therapeutics Ltd | Phase 1 / Phase 2 |
| Unknown | EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRP NCT05150236 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Phase 2 |
| Active Not Recruiting | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts NCT05288166 | Eli Lilly and Company | Phase 3 |
| Unknown | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma NCT05030077 | Tianjin Medical University Second Hospital | Phase 2 |
| Unknown | 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical NCT04831307 | British Columbia Cancer Agency | N/A |
| Unknown | Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) NCT04922047 | RenJi Hospital | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer NCT04519151 | Sheba Medical Center | Phase 2 |
| Completed | High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy NCT04461509 | Alessandro D'Agnolo | Phase 2 |
| Active Not Recruiting | CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood NCT04811846 | University Teaching Hospital Hall in Tirol | N/A |
| Completed | Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial NCT04679675 | Kaiser Permanente | N/A |
| Unknown | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071 | Xiaoxiang Chen | Phase 2 |
| Unknown | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer NCT04566952 | Xiaoxiang Chen | Phase 2 |
| Terminated | Trial of NanoPac Focal Therapy for Prostate Cancer NCT04221828 | NanOlogy, LLC | Phase 2 |
| Unknown | Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk NCT04462926 | Azienda Ospedaliero-Universitaria di Modena | N/A |
| Recruiting | Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) NCT04235777 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment NCT04435964 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Unknown | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma NCT04644432 | Herlev and Gentofte Hospital | Phase 2 |
| Terminated | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947 | Poseida Therapeutics, Inc. | Phase 1 |
| Completed | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NCT03636256 | NanOlogy, LLC | Phase 1 / Phase 2 |
| Completed | Potential Therapeutic Response In Urogenital Tumors NCT03551457 | University of Campinas, Brazil | — |
| Completed | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer NCT03562897 | Catalysis SL | Phase 2 |
| Completed | Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer NCT03081858 | Lipac Oncology LLC | Phase 1 / Phase 2 |
| Completed | Health Gatherings - For Your Health After Cancer NCT03344757 | University of Miami | N/A |
| Terminated | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer NCT02543645 | Celldex Therapeutics | Phase 1 |
| Terminated | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma NCT02386111 | Celldex Therapeutics | Phase 1 |
| Completed | Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients NCT02444195 | University of Michigan | N/A |
| Active Not Recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Inj NCT02266745 | Promontory Therapeutics Inc. | Phase 2 |
| Terminated | Protection of Rectum From High Radiation Doses Using a Spacer NCT01918605 | University of Oulu | N/A |
| Terminated | Alkagin Paste in the Prevention of Radiation Dermatitis NCT01408407 | Dr. Te Vuong | Phase 2 |
| Withdrawn | Acupuncture for the Immune System in Radiation Cancer Patients NCT01422928 | British Columbia Cancer Agency | Phase 3 |
| Terminated | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer NCT00672009 | Cedars-Sinai Medical Center | Phase 2 |
| Completed | Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients NCT01523652 | Azienda Ospedaliera San Giovanni Battista | — |
| Completed | A Trial for Patients With Advanced/Recurrent Endometrial Cancer NCT00377520 | Eli Lilly and Company | Phase 2 |
| Completed | Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy NCT01316458 | Novartis Pharmaceuticals | Phase 2 |
| No Longer Available | Expanded Access to NanoDoce NCT04060628 | NanOlogy, LLC | — |
| Completed | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer NCT00134186 | Pharmacyclics LLC. | Phase 2 |
| Approved For Marketing | Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer NCT01217697 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | — |
| Withdrawn | SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolut NCT02254915 | Medical Enterprises Europe B.V. | Phase 3 |